Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 81
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02017236 | A Food Effect Phase I Study of the Volitinib in Healthy Subjects | ||
| NCT04755075 | Surufatinib Hepatic Impairment Study | ||
| NCT02614495 | Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma | ||
| NCT02133157 | Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors | ||
| NCT03951623 | The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients | ||
| NCT04755088 | Surufatinib Renal Impairment Study | ||
| NCT02590965 | A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | ||
| NCT04169672 | Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors | ||
| NCT02691299 | A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | ||
| NCT01805791 | A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis | ||
| NCT03231501 | HMPL-813 in Treating Patients With Glioblastoma | ||
| NCT04322539 | A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | ||
| NCT04923932 | Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients | ||
| NCT05535933 | HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | ||
| NCT02374645 | A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC | ||
| NCT02196688 | Study of Fruquintinib in Patients With Metastatic Colorectal Cancer | ||
| NCT01985555 | Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors | ||
| NCT03684967 | Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC | ||
| NCT05015621 | A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma | ||
| NCT03128164 | A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed | ||
| NCT01975077 | A Phase Ib Study of Fruquintinib in 3rd Line mCRC | ||
| NCT02966821 | Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma | ||
| NCT02897479 | A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer | ||
| NCT00655733 | Phase II Study of HMPL-004 in Subjects With Crohn's Disease | ||
| NCT03483948 | Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia | ||
| NCT02976116 | A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer | ||
| NCT05277454 | Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT | ||
| NCT02601274 | Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor | ||
| NCT03976856 | Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib | ||
| NCT05173142 | HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors | ||
| NCT02689752 | A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib | ||
| NCT02105129 | A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523 | ||
| NCT03977090 | Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer | ||
| NCT03778229 | Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | ||
| NCT02857998 | A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms | ||
| NCT03251378 | A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers | ||
| NCT04290325 | HMPL-453 in Advanced Malignant Mesothelioma | ||
| NCT01773018 | Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors | ||
| NCT02590952 | A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors | ||
| NCT05009836 | Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC | ||
| NCT04923945 | Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients | ||
| NCT03223376 | A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) | ||
| NCT02589821 | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors | ||
| NCT05318820 | A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers | ||
| NCT02631642 | A Study of HMPL-689 in Healthy Volunteers | ||
| NCT04557397 | Fruquintinib CYP3A Inhibitor and Inducer Study | ||
| NCT03091192 | Savolitinib vs. Sunitinib in MET-driven PRCC. | ||
| NCT03160833 | A Study of HMPL-453 in Patients With Advanced Solid Malignancies | ||
| NCT04716634 | Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors | ||
| NCT02320409 | A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012) |
